Literature DB >> 22753159

Massive hypercoagulable state despite full-dose anticoagulant treatment in a patient with occult malignancy: considerations concerning chemotherapy without definitive diagnosis.

Kathrin Ehren1, Christof Lamberti, Bernd Poetzsch, Michael Majores, Katharina Strach, Tilman Sauerbruch, Jan-Christian Wasmuth.   

Abstract

A 55-year-old female patient presented with recurrent deep venous thrombosis and pulmonary embolism while on oral anticoagulant treatment using the vitamin K antagonist phenprocoumon. Hypercoagulable state was regarded to be paraneoplastic, but no underlying malignancy could be identified despite extensive screening for cancer, including gastroscopy and colonoscopy, a bone marrow biopsy, thoracoabdominal CT scans with subsequent biopsies of possibly malignant findings, octreotide scintigraphy, skeletal scintigraphy and gynaecological screening. In the course of her hospital stay she developed progressive right cardiac insufficiency due to the formation of new thromboses despite aggressive anticoagulant treatment and died of right-sided heart failure. The autopsy showed a poorly differentiated adenocarcinoma in the middle lobe of the right lung. In addition, pulmonary lymphangiosis carcinomatosa, pleural and pericardial carcinosis, and lymph node metastases and osteoblastic vertebral body metastases were shown.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 22753159      PMCID: PMC3027077          DOI: 10.1136/bcr.01.2009.1471

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  15 in total

1.  The risk of a diagnosis of cancer after primary deep venous thrombosis or pulmonary embolism.

Authors:  H T Sørensen; L Mellemkjaer; F H Steffensen; J H Olsen; G L Nielsen
Journal:  N Engl J Med       Date:  1998-04-23       Impact factor: 91.245

2.  Incidence of venous thromboembolism in the year before the diagnosis of cancer in 528,693 adults.

Authors:  Richard H White; Helen K Chew; Hong Zhou; Arti Parikh-Patel; David Harris; Danielle Harvey; Theodore Wun
Journal:  Arch Intern Med       Date:  2005 Aug 8-22

3.  Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study.

Authors:  J A Heit; M D Silverstein; D N Mohr; T M Petterson; W M O'Fallon; L J Melton
Journal:  Arch Intern Med       Date:  2000-03-27

4.  Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data.

Authors:  N Levitan; A Dowlati; S C Remick; H I Tahsildar; L D Sivinski; R Beyth; A A Rimm
Journal:  Medicine (Baltimore)       Date:  1999-09       Impact factor: 1.889

5.  Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study.

Authors:  John A Heit; W Michael O'Fallon; Tanya M Petterson; Christine M Lohse; Marc D Silverstein; David N Mohr; L Joseph Melton
Journal:  Arch Intern Med       Date:  2002-06-10

Review 6.  Thrombosis and cancer: the role of screening for occult cancer and recognizing the underlying biological mechanisms.

Authors:  Agnes Y Y Lee
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2006

7.  The risk of a venous thrombotic event in lung cancer patients: higher risk for adenocarcinoma than squamous cell carcinoma.

Authors:  J W Blom; S Osanto; F R Rosendaal
Journal:  J Thromb Haemost       Date:  2004-10       Impact factor: 5.824

8.  Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients.

Authors:  Alok A Khorana; Charles W Francis; Eva Culakova; Nicole M Kuderer; Gary H Lyman
Journal:  Cancer       Date:  2007-11-15       Impact factor: 6.860

9.  Multifocal strokes as the presentation of occult lung cancer.

Authors:  Babak B Navi; Lisa M DeAngelis; Alan Z Segal
Journal:  J Neurooncol       Date:  2007-07-05       Impact factor: 4.130

10.  Incidence of venous thrombosis in a large cohort of 66,329 cancer patients: results of a record linkage study.

Authors:  J W Blom; J P M Vanderschoot; M J Oostindiër; S Osanto; F J M van der Meer; F R Rosendaal
Journal:  J Thromb Haemost       Date:  2006-03       Impact factor: 5.824

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.